783 related articles for article (PubMed ID: 28645491)
1. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Powles T; Smith K; Stenzl A; Bedke J
Eur Urol; 2017 Oct; 72(4):477-481. PubMed ID: 28413128
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in the Elderly.
Lalani AA; Bossé D; McGregor BA; Choueiri TK
Eur Urol Focus; 2017 Oct; 3(4-5):403-412. PubMed ID: 29183736
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab for the treatment of urothelial cancers.
Teo MY; Rosenberg JE
Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
[TBL] [Abstract][Full Text] [Related]
8. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab as second-line treatment for urothelial cancer.
Mitchell F
Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
[No Abstract] [Full Text] [Related]
11. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
12. Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Nguyen V; Huq M
J Oncol Pharm Pract; 2019 Jul; 25(5):1066-1075. PubMed ID: 29726785
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in medical therapy for metastatic urothelial cancer.
Yuasa T; Urakami S; Yonese J
Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
16. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
17. [Immunooncology in Urologic Cancers: Current Status].
Grimm MO
Aktuelle Urol; 2016 Sep; 47(5):374-7. PubMed ID: 27680188
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
19. [Renaissance of immuno-oncology for urological tumors : Current status].
Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
[TBL] [Abstract][Full Text] [Related]
20. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
